Payment overview · 2025
General Payments
$304.86
14 reported records · 12 companies
Healthcare provider profile · identity verified
Tyson Charles Purdy, MD
Allopathic & Osteopathic Physicians|Family Medicine · LUBBOCK, TX · NPI 1346402328
Verified facts
What the public records show
CMS Open Payments records show Tyson Charles Purdy, MD received $304.86 in general payments during 2025 across 14 reported records.
ABBVIE INC. accounted for 19.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Rexulti, Trintellix, Veozah, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Myrbetriq by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Veozah as an associated drug or biological on 82795 records involving 35863 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Veozah by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Trulicity by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $59.77 | 19.6% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $57.78 | 18.9% | 2 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $34.96 | 11.5% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $19.37 | 6.3% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.27 | 6.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.96 | 6.2% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.95 | 5.9% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $17.05 | 5.6% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $15.77 | 5.2% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $15.00 | 4.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.53 | 4.8% | 1 | 2025 |
| SI-BONE, INC. | Unresolved — no canonical attribution shown | $14.45 | 4.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $304.86 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $59.77 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $57.78 | 2 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $34.96 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $19.37 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $19.27 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.96 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.96 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.95 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $17.05 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $15.77 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $15.00 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $14.53 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $14.53 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $14.53 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 65 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Veozah veozah |
2025 | Veozah | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Veozah open payments reported associated product |
CMS Open Payments — General Payments 82795 supporting records · 35863 recipient NPIs · example record 1238560678 |
Veozah · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
58 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
65 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
82 | 15 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
125 | 29 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 639 | 142 |
| Atorvastatin Calcium | Atorvastatin Calcium | 536 | 137 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 460 | 78 |
| Gabapentin | Gabapentin | 398 | 102 |
| Furosemide | Furosemide | 310 | 84 |
| Lisinopril | Lisinopril | 281 | 87 |
| Pantoprazole Sodium | Pantoprazole Sodium | 281 | 76 |
| Potassium Chloride | Potassium Chloride | 271 | 78 |
| Amlodipine Besylate | Amlodipine Besylate | 260 | 78 |
| Meloxicam | Meloxicam | 259 | 73 |
| Alprazolam | Alprazolam | 243 | 50 |
| Trazodone Hcl | Trazodone Hcl | 221 | 59 |
| Metoprolol Succinate | Metoprolol Succinate | 196 | 66 |
| Tramadol Hcl | Tramadol Hcl | 196 | 55 |
| Tamsulosin Hcl | Tamsulosin Hcl | 183 | 52 |
| Escitalopram Oxalate | Escitalopram Oxalate | 176 | 50 |
| Omeprazole | Omeprazole | 175 | 52 |
| Metformin Hcl | Metformin Hcl | 167 | 51 |
| Duloxetine Hcl | Duloxetine Hcl | 165 | 42 |
| Losartan Potassium | Losartan Potassium | 164 | 53 |
| Hydrochlorothiazide | Hydrochlorothiazide | 158 | 61 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 156 | 49 |
| Montelukast Sodium | Montelukast Sodium | 154 | 40 |
| Buspirone Hcl | Buspirone Hcl | 151 | 37 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 138 | 46 |
| Allopurinol | Allopurinol | 135 | 34 |
| Tizanidine Hcl | Tizanidine Hcl | 130 | 50 |
| Quetiapine Fumarate | Quetiapine Fumarate | 127 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 126 | 28 |
| Eliquis | Apixaban | 125 | 29 |
| Donepezil Hcl | Donepezil Hcl | 119 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 116 | 31 |
| Carvedilol | Carvedilol | 101 | 24 |
| Pregabalin | Pregabalin | 93 | 26 |
| Memantine Hcl | Memantine Hcl | 91 | 23 |
| Azithromycin | Azithromycin | 86 | 78 |
| Fluticasone Propionate | Fluticasone Propionate | 85 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 84 | 31 |
| Trulicity | Dulaglutide | 82 | 15 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 78 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 72 | 17 |
| Amoxicillin | Amoxicillin | 68 | 58 |
| Simvastatin | Simvastatin | 66 | 24 |
| Mounjaro | Tirzepatide | 65 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 65 | 58 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 64 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 63 | 40 |
| Glipizide | Glipizide | 63 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 63 | 14 |
| Celecoxib | Celecoxib | 62 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 62 | 15 |
| Prednisone | Prednisone | 62 | 46 |
| Ozempic | Semaglutide | 60 | 14 |
| Jardiance | Empagliflozin | 58 | 21 |
| Sertraline Hcl | Sertraline Hcl | 58 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 56 | 15 |
| Clonazepam | Clonazepam | 55 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 55 | 22 |
| Ondansetron Odt | Ondansetron | 55 | 23 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 54 | 15 |
| Xarelto | Rivaroxaban | 54 | suppressed |
| Cephalexin | Cephalexin | 52 | 29 |
| Diclofenac Sodium | Diclofenac Sodium | 52 | 15 |
| Temazepam | Temazepam | 50 | suppressed |
| Mirtazapine | Mirtazapine | 49 | 17 |
| Famotidine | Famotidine | 48 | suppressed |
| Lorazepam | Lorazepam | 48 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 48 | 17 |
| Finasteride | Finasteride | 47 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 47 | 17 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 46 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 46 | suppressed |
| Diazepam | Diazepam | 45 | 11 |
| Myrbetriq | Mirabegron | 45 | suppressed |
| Atenolol | Atenolol | 44 | suppressed |
| Bupropion Xl | Bupropion Hcl | 43 | 12 |
| Alendronate Sodium | Alendronate Sodium | 41 | suppressed |
| Eszopiclone | Eszopiclone | 40 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 40 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 40 | 25 |
| Levetiracetam | Levetiracetam | 39 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 38 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 37 | suppressed |
| Estradiol | Estradiol | 37 | suppressed |
| Bumetanide | Bumetanide | 36 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 35 | suppressed |
| Spironolactone | Spironolactone | 35 | 14 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 34 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 33 | 12 |
| Sucralfate | Sucralfate | 32 | 11 |
| Vraylar | Cariprazine Hcl | 32 | suppressed |
| Januvia | Sitagliptin Phosphate | 31 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 30 | suppressed |
| Fluconazole | Fluconazole | 30 | 18 |
| Ibuprofen | Ibuprofen | 30 | suppressed |
| Baclofen | Baclofen | 29 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 29 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Latanoprost | Latanoprost | 27 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 27 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 27 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Cefdinir | Cefdinir | 26 | 21 |
| Metformin Hcl Er | Metformin Hcl | 26 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 26 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 26 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 23 |
| Divalproex Sodium | Divalproex Sodium | 25 | 11 |
| Enalapril Maleate | Enalapril Maleate | 25 | suppressed |
| Nystatin | Nystatin | 25 | 20 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | 18 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 18 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Levofloxacin | Levofloxacin | 23 | 19 |
| Methocarbamol | Methocarbamol | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 22 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Entresto | Sacubitril/Valsartan | 21 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 21 | suppressed |
| Methylprednisolone | Methylprednisolone | 21 | 16 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 20 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 20 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 15 |
| Glimepiride | Glimepiride | 19 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 19 | suppressed |
| Olanzapine | Olanzapine | 19 | 11 |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Movantik | Naloxegol Oxalate | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 15 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Febuxostat | Febuxostat | 15 | suppressed |
| Lactulose | Lactulose | 15 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 13 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Ingrezza | Valbenazine Tosylate | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Rexulti | Brexpiprazole | 13 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 13 | 11 |
| Tiotropium Bromide | Tiotropium Bromide | 13 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 13 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Klor-Con 10 | Potassium Chloride | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Lamotrigine Er | Lamotrigine | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 12 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 11 | suppressed |
| Desloratadine | Desloratadine | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Indomethacin | Indomethacin | 11 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Np Thyroid | Thyroid,pork | 11 | suppressed |
| Nystop | Nystatin | 11 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
| Veozah | Fezolinetant | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $304.86 · 14 records | ABBVIE INC. | ABRYSVO, Auvelity, COMIRNATY, Dexcom G6 Transmitter, Kerendia, Leqembi, MOUNJARO, PREVNAR 20, REXULTI, Senza, TRINTELLIX, VRAYLAR, Veozah, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error